{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:17:49Z","timestamp":1773850669049,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.mehy.2017.10.030","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T21:23:00Z","timestamp":1509484980000},"page":"46-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson\u2019s disease"],"prefix":"10.1016","volume":"110","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willi","family":"Kohlhepp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Pt 8","key":"10.1016\/j.mehy.2017.10.030_b0005","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.mehy.2017.10.030_b0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00023210-200317100-00004","article-title":"Neuroprotective strategies in Parkinson's disease : an update on progress","volume":"17","author":"Mandel","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.mehy.2017.10.030_b0015","article-title":"Projection of the prevalence of Parkinson's disease in the coming decades: revisited","author":"Rossi","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.mehy.2017.10.030_b0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fnagi.2016.00147","article-title":"Prodromal markers in Parkinson's disease: limitations in longitudinal studies and lessons learned","volume":"8","author":"Heinzel","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.mehy.2017.10.030_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/mds.27035","article-title":"Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts","author":"Pilotto","year":"2017","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.mehy.2017.10.030_b0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-017-1684-z","article-title":"Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease","volume":"133","author":"Doppler","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.mehy.2017.10.030_b0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1468-1331.2012.03798.x","article-title":"The PRIPS study: screening battery for subjects at risk for Parkinson's disease","volume":"20","author":"Berg","year":"2013","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.mehy.2017.10.030_b0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.26077","article-title":"The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study)","volume":"30","author":"Pont-Sunyer","year":"2015","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.mehy.2017.10.030_b0045","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5","article-title":"Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study","volume":"15","author":"Shiba","year":"2000","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.mehy.2017.10.030_b0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000007896","article-title":"[123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients","volume":"39","author":"Muller","year":"1998","journal-title":"Eur Neurol"},{"key":"10.1016\/j.mehy.2017.10.030_b0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.parkreldis.2016.07.002","article-title":"Scan without evidence of dopaminergic deficit: a 10-year retrospective study","volume":"31","author":"Nicastro","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"10.1016\/j.mehy.2017.10.030_b0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1590\/S0004-282X2012000900004","article-title":"Dopamine transporter imaging in clinically unclear cases of parkinsonism and the importance of scans without evidence of dopaminergic deficit (SWEDDs)","volume":"70","author":"Utiumi","year":"2012","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"10.1016\/j.mehy.2017.10.030_b0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.114.218966","article-title":"Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus","volume":"351","author":"Stansley","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.mehy.2017.10.030_b0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-148X.2011.00898.x","article-title":"L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions","volume":"25","author":"Slominski","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"10.1016\/j.mehy.2017.10.030_b0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0304-3940(98)00649-1","article-title":"Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra?","volume":"253","author":"Ikemoto","year":"1998","journal-title":"Neurosci Lett"},{"issue":"9","key":"10.1016\/j.mehy.2017.10.030_b0080","doi-asserted-by":"crossref","first-page":"e45183","DOI":"10.1371\/journal.pone.0045183","article-title":"The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells","volume":"7","author":"Pan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.mehy.2017.10.030_b0085","doi-asserted-by":"crossref","DOI":"10.1097\/WNF.0000000000000233","article-title":"Determination of monoamine oxidase A and B activity in long-term treated patients with Parkinson disease","author":"Muller","year":"2017","journal-title":"Clin Neuropharmacol"},{"issue":"20","key":"10.1016\/j.mehy.2017.10.030_b0090","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.0b013e318292a31d","article-title":"Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD","volume":"80","author":"Loane","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mehy.2017.10.030_b0095","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1148\/radiol.2016160662","article-title":"In vivo assessment of brainstem depigmentation in parkinson disease: potential as a severity marker for multicenter studies","volume":"283","author":"Schwarz","year":"2017","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.mehy.2017.10.030_b0100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ene.12613","article-title":"Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients","volume":"22","author":"Reimao","year":"2015","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.mehy.2017.10.030_b0105","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/mds.24954","article-title":"Premotor Parkinson's disease: concepts and definitions","volume":"27","author":"Siderowf","year":"2012","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.mehy.2017.10.030_b0110","doi-asserted-by":"crossref","first-page":"37139","DOI":"10.1038\/srep37139","article-title":"Proteomic characterization of neuromelanin granules isolated from human substantia nigra by laser-microdissection","volume":"14","author":"Plum","year":"2016","journal-title":"Sci Rep"},{"issue":"Pt 1","key":"10.1016\/j.mehy.2017.10.030_b0115","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1093\/brain\/awv251","article-title":"Skin biopsies in the differential diagnosis of parkinsonism: are we ready for simplified protocols?","volume":"139","author":"Doppler","year":"2016","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.mehy.2017.10.030_b0120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jnen\/nlx021","article-title":"Spine topographical distribution of skin alpha-synuclein deposits in idiopathic parkinson disease","volume":"76","author":"Donadio","year":"2017","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.1016\/j.mehy.2017.10.030_b0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cell.2005.09.028","article-title":"Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration","volume":"123","author":"Chandra","year":"2005","journal-title":"Cell"},{"issue":"376","key":"10.1016\/j.mehy.2017.10.030_b0130","doi-asserted-by":"crossref","first-page":"ra45","DOI":"10.1126\/scisignal.2005965","article-title":"Activation of MyD88-dependent TLR1\/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders","volume":"8","author":"Daniele","year":"2015","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.mehy.2017.10.030_b0135","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00401-012-0963-y","article-title":"Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity","volume":"123","author":"Gaugler","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.mehy.2017.10.030_b0140","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1073\/pnas.0536383100","article-title":"Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease","volume":"100","author":"Kirik","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.mehy.2017.10.030_b0145","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1073\/pnas.1200575109","article-title":"Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons","volume":"109","author":"Lundblad","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.mehy.2017.10.030_b0150","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.mehy.2017.10.030_b0155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jnc.13772","article-title":"Pathogenic mechanisms of prion protein, amyloid-beta and alpha-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers","volume":"139","author":"Ugalde","year":"2016","journal-title":"J Neurochem"},{"issue":"6","key":"10.1016\/j.mehy.2017.10.030_b0160","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/ern.13.50","article-title":"Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease","volume":"13","author":"Muller","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.mehy.2017.10.030_b0165","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1471-4159.2010.07132.x","article-title":"The relevance of iron in the pathogenesis of Parkinson's disease","volume":"118","author":"Sian-Hulsmann","year":"2011","journal-title":"J Neurochem"},{"key":"10.1016\/j.mehy.2017.10.030_b0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/B978-0-12-411512-5.00017-8","article-title":"Stress-triggered changes in peripheral catecholaminergic systems","volume":"68","author":"Kvetnansky","year":"2013","journal-title":"Adv Pharmacol"},{"issue":"5","key":"10.1016\/j.mehy.2017.10.030_b0175","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.neuro.2012.08.002","article-title":"Association between polychlorinated biphenyls and Parkinson's disease neuropathology","volume":"33","author":"Hatcher-Martin","year":"2012","journal-title":"Neurotoxicology"},{"issue":"2","key":"10.1016\/j.mehy.2017.10.030_b0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1468-1331.2006.01569.x","article-title":"Chronic subthalamic high-frequency deep brain stimulation in Parkinson's disease\u2013a histopathological study","volume":"14","author":"Nielsen","year":"2007","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.mehy.2017.10.030_b0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00702-003-0102-y","article-title":"Diagnostic staging of Parkinson's disease: conceptual aspects","volume":"111","author":"Przuntek","year":"2004","journal-title":"J Neural Transm"},{"issue":"6","key":"10.1016\/j.mehy.2017.10.030_b0190","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00702-017-1701-3","article-title":"Benefit on motor and non-motor behavior in a specialized unit for Parkinson's disease","volume":"124","author":"Muller","year":"2017","journal-title":"J Neural Transm (Vienna)"},{"issue":"374","key":"10.1016\/j.mehy.2017.10.030_b0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jns.2017.01.018","article-title":"The sleeping brain in Parkinson's disease: a focus on REM sleep behaviour disorder and related parasomnias for practicing neurologists","volume":"15","author":"Bhidayasiri","year":"2017","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.mehy.2017.10.030_b0200","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neurobiolaging.2006.11.013","article-title":"Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia","volume":"29","author":"Klegeris","year":"2008","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.mehy.2017.10.030_b0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","article-title":"Catechol-O-methyltransferase inhibitors in Parkinson's disease","volume":"75","author":"Muller","year":"2015","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.mehy.2017.10.030_b0210","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/WCO.0000000000000389","article-title":"Gut microbiota, 1013 new pieces in the Parkinson's disease puzzle","volume":"29","author":"Scheperjans","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.mehy.2017.10.030_b0215","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/14737175.2016.1163220","article-title":"Clinical drug research in chronic central neurodegenerative disorders","volume":"16","author":"Muller","year":"2016","journal-title":"Expert Rev Neurother"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987717310459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987717310459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T18:17:27Z","timestamp":1529518647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987717310459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":43,"alternative-id":["S0306987717310459"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2017.10.030","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2017.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}